

KV PHARMACEUTICAL CO /DE/
Form SC 13G
October 11, 2005

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

KV Pharmaceutical Co
(Name of Issuer)

Common
(Title of Class of Securities)

482740206
(CUSIP Number)

Check the following box if a fee is being paid with this statement /X/.
(A fee is not required only if the filing person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.)
(See Rule 13d-7).

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. 482740206

13G

Page 2 of 5 Pages

1) NAME OF REPORTING PERSON
S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Neuberger & Berman L.P.
13-5521910

2) CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a) /___/
(b) /X/

Edgar Filing: KV PHARMACEUTICAL CO /DE/ - Form SC 13G

3) SEC USE ONLY

4) CITIZENSHIP OR PLACE OF ORGANIZATION
New York, New York

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

5) SOLE VOTING POWER
371,924

6) SHARED VOTING POWER
3,676,540

7) SOLE DISPOSITIVE POWER
0

8) SHARED DISPOSITIVE POWER
5,913,136

9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
5,913,136

10) CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
146,424

11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
16.35

12) TYPE OF REPORTING PERSON*
BD/IA

CUSIP No. 482740206 13G Page 3 of 5 Pages

Item 1. (a) Name of Issuer:

KV Pharmaceutical Co

Item 1 (b) Address of Issuer's Principal Executive Offices:

2503 S HANLEY RD ST LOUIS MO 63144

Item 2. (a) Name of Person Filing:

Neuberger & Berman L.P.

Item 2 (b) Address of Principal Business Office:

605 Third Ave., New York, NY, 10158-3698

Item 2 (c) Citizenship:

USA

Item 2 (d) Title of Class of Securities:

Edgar Filing: KV PHARMACEUTICAL CO /DE/ - Form SC 13G

Common

- Item 2 (e) CUSIP Number:
482740206
- Item 3. (a) /X/ Broker or Dealer registered under Section 15 of the Act
- Item 3 (b) /X/ Investment Adviser registered under Section 203 of the
Investment Advisers Act of 1940
- Item 4. Ownership:
- (a) Amount Beneficially Owned:
5,913,136
- (b) Percent of Class:
16.35

CUSIP No. 482740206

13G

Page 4 of 5 Pages

- (c) Number of Shares as to which such person has:
- (I) Sole Power to vote or to direct the
vote: 371,924
- (ii) Shared Power to vote or to direct the
vote: 3,676,540
- (iii) Sole Power to dispose or to direct the disposition
of: 0
- (iv) Shared Power to dispose or to direct the disposition
of: 5,913,136

Item 5. Ownership of Five Percent or Less of a Class:
N/A

Item 6. Ownership of More than Five Percent on Behalf of Another:

Neuberger & Berman L.P. is deemed to be a beneficial owner for purpose of Rule 13(d) since it has shared power to make decisions whether to retain or dispose of the securities of many unrelated clients. Neuberger & Berman L.P. does not, however have any economic interest in the securities of those clients. The clients are the actual owners of the securities and have the sole right to receive and the power to direct the receipt of dividends from or proceeds from the sale of such securities.

With regard to the shares set forth under Item 4.(c)(II), Neuberger & Berman L.P. and Neuberger & Berman Management Inc. are deemed to be beneficial owners for purposes of Rule 13(d) since they both have shared power to make

Edgar Filing: KV PHARMACEUTICAL CO /DE/ - Form SC 13G

decisions whether to retain or dispose of the securities. Neuberger & Berman L.P. and Neuberger & Berman Management Inc. serve as sub-adviser and investment manager, respectively, of Neuberger & Berman's various Funds which hold such shares in the ordinary course of their business and not with the purpose nor with the effect of changing or influencing the control of the issuer.

No other Neuberger & Berman L.P. advisory client has an interest of more than 5% of the issuer.

It should be further noted that the share calculation under item 4.(c)(IV) is derived from a total combination of the shares set forth under Item 4.(c)(I and II). The remaining balance of shares, if any, are for individual client accounts over which Neuberger & Berman L.P. has shared power to dispose.

CUSIP No. 482740206

13G

Page 5 of 5 Pages

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company:

N/A

Item 8. Identification and Classification of Members of the Group:

N/A

Item 9. Notice of Dissolution of Group:

N/A

Item 10. Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired in the ordinary course of business and were not acquired for the purpose of and do not have the effect of changing or influencing the control of the issuer of such securities and were not acquired in connection with or as a participant in any transaction having such purposes or effect.

Signature:

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: September 30, 2005

By: _____

C. Carl Randolph

General Partner

Name/Title